A. Zalcenstein

发表

Oral DeliveryWith Novel Solid Dispersions: Stable Self-Assembled Formulations of Lipophilic Drugs With Improved Bioperformance

A. Berman, Galia Temtsin Krayz, M. Averbuch, 2009 .

Nitric oxide promotes p53 nuclear retention and sensitizes neuroblastoma cells to apoptosis by ionizing radiation

M. Oren, Xinjiang Wang, X. Wang, 2003, Cell Death and Differentiation.

Repression of the MSP/MST-1 gene contributes to the antiapoptotic gain of function of mutant p53

V. Rotter, M. Oren, P. Stambolsky, 2006, Oncogene.

The PI3K inhibitor LY294002 prevents p53 induction by DNA damage and attenuates chemotherapy-induced apoptosis

M. Oren, S. Wilder, R. Seger, 2005, Cell Death and Differentiation.

Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants

V. Rotter, M. Oren, P. Krammer, 2003, Oncogene.

Transactivation of the EGR1 Gene Contributes to Mutant p53 Gain of Function

V. Rotter, N. Goldfinger, M. Oren, 2004, Cancer Research.

The c-fos Proto-Oncogene Is a Target for Transactivation by the p53 Tumor Suppressor

D. Israeli, M. Oren, S. Wilder, 1999, Molecular and Cellular Biology.

Transactivation by the p53 Tumor Proto-Oncogene Is a Target for fos The c-

D. Israeli, M. Oren, T. Juven-Gershon, 2014 .

SOLUMER™ TECHNOLOGY: A VIABLE ORAL DOSAGE FORM OPTION FOR BCS CLASS II MOLECULES

Amir Zalcenstein, A. Zalcenstein, 2011 .